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Abstract
Background—Cell therapy for cardiovascular disease has been limited by low engraftment of
administered cells and modest therapeutic effects. Bone marrow (BM) -derived CD31+ cells are a
promising cell source owing to their high angiovasculogenic and paracrine activities.
Objective—This study sought to identify culture conditions that could augment the cell adhesion,
angiogenic, and anti-inflammatory activities of BM-derived CD31+ cells, and to determine
whether these cultured CD31+ cells are effective for cardiac and vascular repair.
Methods—CD31+ cells were isolated from human BM by magnetic-activated cell sorting and
cultured for 10 days under hematopoietic stem cell, mesenchymal stem cell, or endothelial cell
culture conditions. These cells were characterized by adhesion, angiogenesis, and inflammatory
assays. The best of the cultured cells were implanted into myocardial infarction (MI) and hindlimb
ischemia (HLI) models to determine therapeutic effects and underlying mechanisms.
Results—The CD31+ cells cultured in endothelial cell medium (EC-CD31+ cells) showed the
highest adhesion and angiogenic activities and lowest inflammatory properties in vitro compared
with uncultured or other cultured CD31+ cells. When implanted into mouse MI or HLI models,
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EC-CD31+ cells improved cardiac function and repaired limb ischemia to a greater extent than
uncultured CD31+ cells. Histologically, injected EC-CD31+ cells exhibited higher retention,
neovascularization, and cardiomyocyte proliferation. Importantly, cell retention and endothelial
transdifferentiation was sustained up to 1 year.
Conclusions—Short-term cultured EC-CD31+ cells have higher cell engraftment, vessel-
formation, cardiomyocyte proliferation, and anti-inflammatory potential, are highly effective for
both cardiac and peripheral vascular repair, and enhance survival of mice with heart failure. These
cultured CD31+ cells may be a promising source for treating ischemic cardiovascular diseases.
Keywords
angiogenesis; CD31; engraftment; inflammation; myocardial infarction; peripheral vascular
disease
Cell therapy has emerged as a promising new strategy for regenerating damaged ischemic
tissue. Experimental studies and pilot clinical trials with various bone marrow (BM) cells,
BM-mononuclear cells (MNCs), early endothelial progenitor cells (EPCs), or mesenchymal
stem cells (MSCs) have shown favorable effects on cardiac repair after myocardial
infarction (MI) (1,2). Mechanistically, paracrine actions are now known to be the main
mechanism underlying ischemic tissue repair (3-6).
Recent meta-analyses of clinical trials for cardiac cell therapy with BM cells showed that
left ventricular ejection fraction improved only ∼4% (7). Interestingly, selected populations
such as CD34+ and CD133+ (also known as prominin 1 [PROM]) cells did not show
significant therapeutic advantages over controls; rather, BM-MNCs and EPCs were more
effective than controls. These results are not surprising given that paracrine (rather than
transdifferentiation) effects are the main mechanism for BM cell therapy, and further
suggest that selection of stem or progenitor cells may not be necessary when using BM-
derived cells (5,6). We recently reported that BM-derived or peripheral blood-derived
MNCs that express CD31 (also known as platelet endothelial cell adhesion molecule 1
[PECAM1]) on the surface are a specific cell population enriched with angiovasculogenic
properties (8,9). Although they include a small stem cell population (<2%), the majority of
CD31+ cells are lineage-committed and constitute ∼25% of total MNCs. We found that
these cells are more effective than BM-MNCs or BM-CD31 cells for repairing limb
ischemia.
However, collective data have shown that there is still much room for improvement in
therapeutic efficacy. Specifically, low cell retention in vivo is a major limiting factor for
cardiac cell therapy (10), and vessel-forming capability also needs improvement. Moreover,
despite its importance, the need to reduce inflammation is relatively underestimated and thus
underdeveloped (11).
Accordingly, this study was designed to improve the function of newly identified CD31+
cells by cell culture. Specifically, we sought to find culture conditions to induce higher
adhesive, angiogenic, and vasculogenic, but lower inflammatory, activities. We also aimed
to determine the therapeutic capability of the cultured CD31+ cells in the treatment of
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ischemic heart and vascular disease. In addition to the well-known paracrine or humoral
effects of the cells, we also addressed important and long-debated mechanistic issues:
endothelial transdifferentiation and long-term fate of the implanted BM cells in tissues
(12,13). The present study demonstrated that CD31+ cells cultured under specific endothelial
cell media exhibited the augmented cell biological characteristics mentioned in the
preceding text and are effective for repairing experimental MI and limb ischemia.
Methods
An expanded Methods section is available in the Online Appendix.
Isolation and Cultivation of CD31+ Cells
Fresh human BM samples were purchased from Lonza (Walkersville, Maryland). Isolation
of CD31+ cells was performed using magnetic activated cell sorting (MACS; Miltenyi
Biotec, Auburn, California) with a CD31 antibody, as we previously described (9). CD31+
cells were plated at a density of 1 × 106 cells/cm2 on plates in EBM-2 basal medium
supplemented with EGM-2 SingleQuots (Lonza) and 15% fetal bovine serum (FBS) for the
endothelial cell (EC) culture conditions. In the MSC culture conditions (MC), cells were
grown in Dulbecco’s Modified Eagle’s Medium with low glucose containing 15% FBS. In
the hematopoietic stem cell culture conditions (HC), cells were grown in Iscove’s Modifed
Dulbecco’s Medium supplemented with 10% FBS, stem cell factor (50 ng/ml),
thrombopoietin (20 ng/ml), and Fms-related tyrosine kinase 3 ligand (FLT3LG; 20 ng/ml).
All of the subsequent assays were performed with 10-day cultured CD31+ cells.
Cell Adhesion Assay and Matrigel Network Formation Assay
See the Online Appendix.
Flow Cytometry Analysis
See the Online Appendix.
Quantitative Rt-Pcr (Qrt-Pcr) Assay
See the Online Appendix.
Cell Transplantation in Myocardial Infarction and Hindlimb Ischemia Models
We performed MI and cell transplantation as described previously (6,14). See the Online
Appendix.
Histological Analysis
See the Online Appendix.
Flow Cytometry Analysis of Digested Tissues
See the Online Appendix.
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Statistical Analysis
See the Online Appendix.
Results
Cell Biological Characteristics of CD31+ Cells Cultured Under Various Conditions
To investigate the adhesive, vasculogenic, and proliferative capacity of CD31+ cells, we
isolated CD31+ cells from human BM-MNCs using MACS. The purity of CD31+ cells was
97.6 ± 1.2%. First, we compared the expansion profile of CD31+ cells. The same number of
CD31+ cells was cultivated under 3 culture conditions, MC, EC, and HC. After 7 days of
culture, nonadherent cells were removed in MC and EC. The adherent cells showed
heterogeneous morphology, including round and spindle-shaped cells (Figure 1A). MC-
CD31+ and EC-CD31+ cells grew quickly from day 7 to 25, showing higher proliferation
properties than the HC-CD31+ cells (Figure 1B). CD31+ cells in EC (EC-CD31+) for 10
days expressed endothelial cell proteins von Willebrand factor (VWF), kinase insert domain
receptor (KDR), CDH5 (VE-cadherin), and CD31, but MC-CD31+ and HC-CD31+ did not
express CDH5 or VWF by immunocy-tochemistry (Figure 1C).
As adhesion capacity is an important indicator of cell engraftment and survival in vivo, we
performed an adhesion assay. The number of cells adherent to extracellular matrix proteins
fibronectin, vitronectin, collagen I, and laminin was significantly higher in the MC and EC
groups than the uncultured CD31+ cells (UC) (all p < 0.01) (Figure 1D). We performed
Matrigel tube formation assays with cultured or uncultured CD31+ cells alone or cocultured
with human umbilical vein endothelial cells (HUVECs). Without coculture with HUVECs,
only EC-CD31+J cells showed meaningful tube formation. With coculture with HUVECs,
all cultured CD31+ cells showed higher branching points and tube lengths compared with
the UC (Figure 1E and 1F). When HUVECs were cultured alone on Matrigel under these
conditions, the HUVECS cultured under EC conditions (EC-HUVECs) exhibited higher
branching points and tube lengths compared with the HC-HUVECs and MC-HUVECs
(Figure 1G). These data indicate that CD31+ cells cultured in EC have the highest adhesion
and independent tube-forming capability.
Surface Protein Expression of Cultured and Uncultured CD31+ Cells
To characterize cultured CD31+ cells, we performed flow cytometry analyses. Regardless of
cell culture, CD31+ cells maintained expression of the pan-hematopoietic marker PTPRC
(protein tyrosine phosphatase, receptor type, C, also known as CD45) as well as CD31
(Figure 2). Cells expressing lineage-committed markers CD3 (T cell) or CD19 (B cell) were
decreased during culture. Cells exhibiting stem cell markers CD34, PROM1 (CD133), and
KIT (proto-oncogene c-Kit, or CD117) were maintained in HC but generally decreased in
the other conditions. Under EC, the cell populations expressing hematopoietic-endothelial
markers KDR and TEK (tyrosine kinase, endothelial, or TIE2), monocyte-macrophage
markers ITGAM (integrin alpha M, or CD11b) and CD14, and a dendritic cell marker,
THBD (thrombomodulin, or CD141), were significantly increased, whereas those
expressing ENG (end-oglin, or CD105) and MCAM (melanoma cell adhesion molecule, or
CD146) were not significantly changed. Although MC cells showed similar trends to EC
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with less prominent increases in TEK, KDR, THBD, ITGAM, and CD14, HC cells did not
change or reduced their expression. These data suggest that CD31+ cells cultured under 3
different conditions have distinct characteristics and the EC conditions in general induced
the highest endothelial-monocytic pheno-type shift of CD31+ cells.
Expression of Angiogenic, Integrin, and Inflammatory Genes
To measure mRNA expression, we conducted qRT-PCR. Expression of angiogenic factors
such as basic fibroblast growth factor (FGF2), hepatocyte growth factor (HGF), platelet-
derived growth factor beta (PDGFB), placental growth factor (PlGF), and matrix
metallopeptidase 9 (MMP9) were significantly increased in all culture conditions compared
with the UC (Figure 3A). of note, chemo-kine (C-C motif) ligand 2 (CCL2) and interleukin
8 (IL8), which play important roles in arteriogenesis, were also increased in all conditions
(Figure 3A). Expression of cell survival factors insulin-like growth factor 1 (IGF1) and Ak
strain transforming oncogene (AKT1) were generally increased after culture. We also
measured expression of integrin beta-1 (ITGB1), integrin beta-2 (ITGB2), integrin alpha-5
(ITGA5), and integrin alpha-6 (ITGA6), as these molecules mediate cell-to-cell and cell-to-
extracellular matrix interactions, regulating adhesion and angiogenesis (15,16). These
integrin levels were increased in all culture conditions and were particularly higher in EC
compared with UC (Figure 3B). Expression of representative inflammatory genes IL1B,
IL6, and interferon gamma (IFNG) was decreased in all conditions compared with UC
(Figure 3C). However, anti-inflammatory factors IL10 (17), transforming growth factor
beta-1 (TGFB1) (18), interleukin 1 receptor, type 1 (IL1R1), TNFRSF1A (tumor necrosis
factor receptor 1A), and leukemia inhibitory factor (LIF) were 3-fold to 30-fold increased in
the cultured CD31+ cells, notably in EC (Figure 3D). Collectively, these findings indicate
that cultured CD31+ cells, particularly in EC, are enriched with vessel-formation, cell-
survival, and anti-inflammatory factors.
Favorable Effects of Cultured CD31+ Cells on Repair of Cardiac And Hindlimb Ischemia
We next investigated the therapeutic effects of cultured CD31+ cells on infarct repair. On the
basis of the in vitro data, we selected EC-CD31+ cells cultured for 10 days and compared the
effects to UC-CD31+ cells and phosphate-buffered saline (PBS). After induction of MI in
nude mice, we injected 1 × 106 cells or the same volume of PBS directly into the peri-infarct
area. Echocardiography at 3 weeks after cell transplantation demonstrated that left
ventricular end-diastolic dimension and left ventricular end-systolic dimension were the
lowest in the EC group, and left ventricular fractional shortening was the highest in the EC
group followed by the UC and PBS groups (Figure 4A and 4B). Compared with the PBS
group, both UC and EC groups showed significantly lower circumferential fibrosis area
examined at 4 weeks, with the smallest in the EC group (Figure 4C and 4D). These results
indicate that intracardiac implantation of uncultured or cultured CD31+ cells can attenuate
cardiac dysfunction and remodeling, with the EC-CD31+ cells having higher potency.
We next evaluated the therapeutic potential of cultured CD31+ cells in HLI. After creating
HLI in nude mice, we injected 10-day cultured EC-CD31+ cells, MC-CD31+ cells, or HC-
CD31+ cells, UC-CD31+ cells, or PBS into the ischemic hindlimbs (1 × 106 cells per
mouse). Laser Doppler perfusion imaging was performed weekly to monitor the ischemic
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hindlimb’s blood flow. Laser Doppler perfusion imaging analysis revealed a greater
recovery of blood perfusion in the EC group compared with each of the other 4 groups
(Online Figure 1A and 1B). Although limb loss was frequently observed in the PBS control
group, the EC group showed a significantly lower limb loss score than the PBS, UC, or MC
groups (Online Figure 1C and 1D). Capillary density in the hindlimb muscle was
significantly higher in the EC group compared with that of the PBS, UC, and MC groups (p
< 0.01 vs. PBS; p < 0.05 vs. UC or MC) (Online Figure 2A). These results suggest that
among all the groups, EC-CD31+ cells have better therapeutic potential for ischemic limb
recovery.
Neovascularization, Cardiac Proliferative and Protective Effects, and Anti-Inflammatory
Effects of Cultured CD31+ Cells
In the MI model, the capillary density at the peri-infarct area at 4 weeks was also highest in
the EC group, followed by the UC and PBS groups (Figure 5A). We determined
cardiomyocyte proliferation and apoptosis with cardiac samples harvested at 2 weeks using
double staining for Ki67 and sarcomeric α-actinin or double staining for terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) and sarcomeric α-actinin,
respectively. The EC group showed significantly higher numbers of Ki67+ car-diomyocytes
compared with the UC and PBS groups (Figure 5B). Apoptotic cardiomyocytes at the peri-
infarct area measured by TUNEL assay were lowest in the EC group, followed by the UC
and PBS groups (Figure 5C). These results suggest that EC-CD31+ cells have robust cardiac
proliferative and protective effects.
To determine other humoral effects of cell transplantation on ischemic hearts, MI mice were
sacrificed and cardiac tissues were collected at 1 week. The expression levels of vascular
endothelial growth factor A (VEGFA), angiopoietin 1 (ANGPT1), PDGFB, IGF1, and
CD31 were significantly increased in the EC group compared with the PBS or UC groups
(Figure 5D). FGF2 was the only factor more highly expressed in the UC group compared
with the EC or PBS groups. Compared with the other groups, the expression of anti-
inflammatory factors IL10 and TGFB1 was significantly higher and that of the
proinflammatory factors IL1B and tumor necrosis factor (TNF) was lower in the EC group
(Figure 5E and 5F). These data indicate that direct cardiac injection of EC-CD31+ cells
augmented multiple biological factors associated with vascularization and anti-inflammation
and reduced proinflammatory factors.
Cultured CD31+ Cells Showed Higher Engraft-Ment And Endothelial Transdifferentiation
Potential
We determined engraftment and trans-differentiation potential in tissue samples harvested
from the heart and the limb muscles at 4 weeks. Histologic analyses demonstrated that
injected 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (Dil)-labeled
EC-CD31+ cells or UC-CD31+ cells were engrafted in both tissues and mainly localized in
the pericytic or perivascular areas of the hearts (Figure 6A) and limb muscles (Online Figure
3A). We also found that a portion of CD31+ cells was incorporated into vessels and
exhibited endothelial marker isolectin B4 (ILB4) (Figure 6B, Online Figure 3B). By
histomorphometric analyses, the numbers of engrafted cells (Dil+ cells) and endothelially
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transdifferentiated cells (Dil+, ILB4+ cells) were significantly higher in the EC group
compared with the UC group (Figure 6B and Online Figure 3B, right panels). To more
precisely quantify the rate of engraftment and transdifferentiation of CD31+ cells, we
conducted flow cytometric analysis on enzymatically digested hearts after systemic injection
of ILB4 as described (8). This analysis again demonstrated that the EC group exhibited ∼ 2-
fold higher engraftment and ∼ 3-fold higher endothelial transdifferentiation rates compared
with the UC group (Figure 6C and 6D). Similar results were found in the histologic and flow
cytometric analyses of the HLI model (Online Figure 3C and 3D). Collectively, these
findings suggest that, compared with uncultured CD31+ cells, EC-CD31+ cells have superior
potency for engraftment and endothelial trans-differentiation.
Long-Term Engraftment and Endothelial Transdifferentiation Potential of CD31+ Cells
We further quantified the long-term engraftment and endothelial transdifferentiation of
cultured CD31+ cells using tissues harvested 1 year after cell transplantation. Contrary to the
prevailing notion that injected BM cells in tissues survive only for a short term, histological
analyses of the heart and hindlimb muscles showed engrafted CD31+ cells, as well as those
expressing ILB4, within the vascular structure (Figure 7A and Online Figure 4A).
Quantitative analyses with flow cytometry after perfusion of ILB4 and enzymatic digestion
of heart and hindlimb muscle revealed an ∼0.6% engraft-ment rate (DiI+ cells per total
cells) (Figure 7B) and ∼2.1% endothelially transdifferentiated cells (DiI+ILB4+ cells)
among total endothelial cells in heart tissues (Figure 7C), and w0.4% engrafted cells (Online
Figure 4B) and w3.7% endothelially trans-differentiated cells in hindlimb muscle (Online
Figure 4C). We also confirmed these results with fluorescence in situ hybridization. Y
chromosome signals derived from human CD31+ cells were detected in nuclei of endothelial
cells as well as in other myocardial cells (Online Figure 5A and 5B). These findings
confirmed the long-term survival and endothelial cell transdifferentiation capabilities of EC-
CD31+ cells in vivo.
Discussion
To improve cardiovascular cell therapy, continuous efforts have been made to identify more
potent cells and to improve their function. This study demonstrated that specific culture
conditions enhance the tissue reparative function of BM-derived hematopoietic CD31+ cells.
In modified endothelial culture conditions, CD31+ cells expressed the highest levels of
adhesion, pro-angiogenic, and anti-inflammatory factors, and the lowest levels of
inflammatory factors compared with uncultured CD31+ cells or CD31+ cells that were
cultured under other conditions. These EC-CD31+ cells, when implanted in vivo, showed
robust neovascularization and cell retention, and induced cardiac and ischemic limb repair to
a greater extent than uncultured CD31+ cells. Of note, mice receiving EC-CD31+ cells after
MI had a significantly higher 7-month survival rate, implying additional clinical benefits of
EC-CD31+ cell therapy for heart failure. Although low, cell survival and endothelial trans-
differentiation capacity was confirmed for up to a year. This is the first report to demonstrate
such long-term engraftment of any injected BM cells and maintenance of the endothelially
transdifferentiated phenotype.
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The original goals of culturing CD31+ cells were to enhance their adhesion and angiogenic-
paracrine capacities. As expected, cultures in the EC conditions augmented both activities in
CD31+ cells. The most notably increased factors were integrins, which are cell adhesion
receptors that interact with extracellular matrices (19) and play a critical role in cell
adhesion, cell survival, endothelial cell migration and proliferation, and matrix
metalloproteinase activation. Integrins also interact with receptors for 2 main angiogenic
factors, VEGF and FGF, to facilitate angiogenesis (16,20). Under EC conditions, multiple
angiogenic, arteriogenic, antiapoptotic, and chemoattractant factors essential for vessel
formation, cell survival, and tissue repair were significantly increased. These higher cell
adhesion and angiogenic activities in the EC-CD31+ cells synergistically functioned to
enhance cell survival, neovascularization, and tissue regeneration in vivo. They further
increased cardiomyocyte proliferation and reduced cardiomyocyte apoptosis. It is also likely
that the enriched paracrine factors, such as IGF1 and HGF, could have activated resident
cardiac stem cells to induce myocardial regeneration (21,22).
To our surprise, key proinflammatory cytokines were suppressed and anti-inflammatory
cytokines were increased in the EC-CD31+ cells. These anti-inflammatory properties are
beneficial for acute cardiovascular tissue repair. After MI, inflammatory cells infiltrate the
ischemic heart tissue and secrete inflammatory cytokines (23). Excessive or prolonged
inflammation in MI leads to cardiac dysfunction. Studies also reported that unselected BM
cell transplantation caused calcification in hearts or ulceration in limbs, which are associated
with proinflammatory activities of the injected cells (24,25). The EC-CD31+ cells highly
expressed anti-inflammatory factors IL10 and TGFB1. IL10 is a well-known anti-
inflammatory cytokine, a representative suppressor of proinflammatory mediators, and has
auspicious effects on cardiac repair (17). TGFB1 is another major regulator controlling
inflammation (18). Anti-inflammation factors, such as IL1R1, TNFRSF1A, and LIF, were
also more highly expressed compared with uncultured CD31+ cells (26,27).
We also observed improved cell engraftment in the cultured CD31+ cells. At 4 weeks, there
were twice as many surviving EC-CD31+ cells as uncultured CD31+ cells in both the MI
and HLI models. Given our prior studies showing 4.5 times higher survival of uncultured
CD31+ cells compared with uncultured CD31 cells (8,9), EC-CD31+ cells have more than 9
times higher cell engraftment potential than the uncultured CD31 cells that comprise 75% of
the most commonly used MNCs for cell therapy. Another important observation is the
endothelial transdifferentiation or vasculogenic potential of EC-CD31+ cells. Although the
transdifferentiation potential of BM-derived cells has been under debate, this study showed
that EC-CD31+ cells retained even higher endothelial transdifferentiation potential than
uncultured CD31+ cells (8,9). Compared with uncultured CD31+ cells, EC-CD31+ cells had
a 3-fold (MI model) to 4-fold (HLI model) higher transdifferentiation rate at 1 month. The
hindlimb muscle showed a substantially higher rate of transdifferentiated ECs than
myocardium (8% vs. 1.5%). These engraftment and transdifferentiation analyses were
extended up to a year. To date, no studies have addressed the long-term fate of direct tissue-
injected BM cells in vivo. Histologic examination of >1000 sections and flow cytometry
analyses demonstrated durable survival and endothelial. transdifferentiation of EC-CD31+
cells in both heart land limb muscle at 1 year.
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Although EC-CD31+ cells were the most effective for ischemic limb recovery, CD31+ cells
cultured under other conditions also were more effective than control cells. Compared with
uncultured CD31+ cells, all cultured CD31+ cells displayed increased angiogenic and
decreased inflammatory properties. However, EC-CD31+ or HC-CD31+ cells have higher
proangiogenic factors and activities than MC-CD31+ cells. The proinflammatory and anti-
inflammatory profiles are similar between HC-CD31+ cells and MC-CD31+ cells, but are
more favorable in EC-CD31+ cells. However, it remains to be determined whether these
cultured cells have different effects on the repair of acute MI according to the culture
conditions.
Study Limitations
Although meta-analyses demonstrated relatively small effects in improvement of ejection
fraction overall for BM cell therapy (7), recent clinical trials with MSCs for ischemic
cardiomyopathy demonstrated various beneficial effects, including enhanced heart failure
score and reduction of scar size and cardiac volume indices (28,29). The current study also
attempted long-term follow-up of cardiac function for a year, but all animals in the UC and
PBS groups died by 7 months, whereas those treated with the EC-CD31+ cell group all
survived. Together, these studies suggested that adult cell therapy remains a viable
therapeutic option, and various parameters other than left ventricular ejection fraction are
needed to appropriately address the advantages of clinical cell therapy.
Conclusions
In conclusion, we demonstrated for the first time that culture-expanded CD31+ cells induced
enhanced adhesion, vessel formation, cardiomyocyte proliferation, and anti-inflammatory
effects, and are effective for repairing cardiovascular damage (Central Illustration). These
cells may be a novel and advanced therapeutic option for treating ischemic cardiovascular
disease.
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Abbreviations and Acronyms
BM bone marrow
Dil 1,1′ - dioctadecyl-3,3,3′,3′ tetramethylindocarbocyanine perchlorate
EC endothelial cell culture conditions
EPCs endothelial progenitor cells
FBS fetal bovine serum
HC hematopoietic stem cell culture conditions
HLI hindlimb ischemia
HUVECs human umbilical vein endothelial cells
MACS magnetic activated cell sorting
MC MSC culture conditions
MI myocardial infarction
MNCs mononuclear cells
MSCs mesenchymal stem cells
PBS phosphate-buffered saline
UC uncultured cells
VWF von Willebrand factor
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Perspectives
Competency in Medical Knowledge
Cell therapy holds promise as a treatment strategy to regenerate damaged ischemic tissue,
but low engraftment of administered cells and modest therapeutic effects are important
limitations. Short-term cultured bone marrow-derived CD31+ cells yielded higher cell
engraftment, vessel formation, cardiomyocyte proliferation, and anti-inflammatory
effects in mouse models of ischemic cardiac and vascular diseases.
Translational Outlook
The clinical efficacy and safety of bone marrow-derived CD31+ cells for tissue salvage
and recovery in patients with ischemic limbs and for restoration of ventricular function
and survival after myocardial infarction should be investigated in future studies.
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Figure 1. In Vitro Cell Biological Characteristics of Cultured and Uncultured CD31+ Cells
(A) Morphologies of CD31+ cells cultured under hematopoietic stem cell (HC),
mesenchymal stem cell (MC), and endothelial cell (EC) conditions at day 10. Bars = 200
µm. (B) Growth curves of HC, MC, and EC. n = 5 per group. **p < 0.01, *p < 0.05 vs. HC.
(C) Endothelial and mesenchymal culture conditions induced CD31+ cells to express
endothelial proteins kinase insert domain receptor (KDR), CDH5, von Willebrand factor
(VWF), and CD31 in culture. (D) Cell adhesion assays showed higher adhesion of EC and
MC to all tested extracellular matrix proteins (fibronectin [FN], vitronectin [VN], type I
collagen [CL], laminin [LN]) compared with uncultured cells (UC). n = 5 per group. Bars =
500 µm. (E) Tube formation potential. Tube lengths and the number of branching points
were measured 24 h after seeding of cultured or uncultured CD31+ cells in Matrigel coated
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plates. n = 5 per group. Bars: 500 µm. (F) Tube formation by coculture with human
umbilical vein endothelial cells (HUVEC). Tube lengths and the number of branching points
were measured 12 hours after seeding of 1,1∼-dioctadecyl-3,3,3∼,3∼-
tetramethylindocarbocyanine perchlorate-labeled cultured or uncultured CD31+ cells in
Matrigel-coated plates. n = 5 per group. Bars: 500 µm. (G) Tube formation assay using
HUVEC only. Tube lengths and the number of branching points were measured 5 hours
after seeding of HUVEC in Matrigel-coated plates. n = 5 per group. **p < 0.01. Bars = 200
µim. (D-F) **p < 0.01 vs. UC, *p < 0.05 vs. UC. AD = adherent; HPF = high-powered field;
UC = uncoated.
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Figure 2. Flow Cytometric Analyses of Cultured and Uncultured CD31+ Cells
(A) Representative histograms of flow cytometry data. The CD31+ cells cultured under the 3
conditions for 10 days were labeled with phycoerythrin-conjugated (red spectra) or
fluorescein isothiocyanate-conjugated (green spectra) antibodies and analyzed by flow
cytometry for hematopoietic and endothelial markers. (B) Quantitative analyses (n = 4
each). ENG = endoglin; ITGAM = integrin alpha M; KIT = proto-oncogene c-Kit; MCAM =
melanoma cell adhesion molecule; PROM1 = prominin 1; PTPRC = protein tyrosine
phosphatase, receptor type, C; TEK = tyrosine kinase, endothelial; THBD =
thrombomodulin. Other abbreviations as in Figure 1.
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Figure 3. Expression of Angiogenic, Integrin, and Inflammatory Factors
Quantitative reverse transcriptase polymerase chain reaction was performed to measure the
level of gene expression from cultured and uncultured CD31+ cells. Various angiogenic (A),
cell adhesion (integrin) (B), proinflammatory (C), and anti-inflammatory (D) factors were
up-regulated or down-regulated in the cultured groups compared with the uncultured group
(n = 4 each; *p < 0.05; **p < 0.01). Individual values were normalized to glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) (+p < 0.05, HC vs. EC; ‡p < 0.01, HC vs. EC; §p <
0.05, EC vs. MC; ¶p < 0.01, EC vs. MC; ‖p < 0.01, MC vs. HC). AKT1 = Ak strain
transforming oncogene; ANGPT1/2 = angiopoietin 1/2;CCL2 = chemokine (C-C motif)
Kim et al. Page 16
J Am Coll Cardiol. Author manuscript; available in PMC 2015 October 21.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
ligand 2; FGF2 = basic fibroblast growth factor; HGF = hepatocyte growth factor; IFNG =
interferon gamma; IGF1 = insulin-like growth factor 1; IL(n) = interleukin (n); IL1R1 =
interleukin 1 receptor, type1; ITGA5/6 = integrin alpha-5/-6; ITGB1/2 = integrin beta-1/-2;
LIF = leukemia inhibitory factor; MMP9 = matrix metallopeptidase 9; PDGFB = platelet-
derived growth factor beta; PlGF = placental growth factor; TGFB1 = transforming growth
factor beta-1; TNF = tumor necrosis factor; TNFRSF1A = tumor necrosis factor receptor
1A; VEGFA = vascular endothelial growth factor A. Other abbreviations as in Figure 1.
Kim et al. Page 17
J Am Coll Cardiol. Author manuscript; available in PMC 2015 October 21.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 4. Endothelial Cell Transplantation Is Effective for Infarct Repair
(A) Representative M-mode echocardiograms. (B) Left ventricular end-diastolic dimension
(LVEDD) and left ventricular end-systolic dimension (LVESD) were lowest in the
endothelial cell (EC) group. Left ventricular fractional shortening (LVFS) was better in EC-
injected hearts compared with uncultured cell (UC)-injected or phosphate-buffered saline
(PBS)-injected hearts at 3 weeks after myocardial infarction (n = 7 each; *p < 0.05). (C)
Representative cross-sectional images of hearts stained with Masson’s trichrome at 4 weeks
after cell transplantation. The blue color represents fibrosis. (D) EC transplantation offered
the highest reduction in fibrosis area (n = 7; *p < 0.05; **p < 0.01).
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Figure 5. Endothelial Cell Transplantation Increased Neovascularization and Cardiomyocyte
Proliferation and Protection, and Suppressed Inflammation In Vivo
(A) Isolectin B4 (ILB4) staining for the peri-infarct regions and quantitative analysis of
capillary density (n = 7 each; *p < 0.05, **p < 0.01). Bars = 50 μm; sarcomeric α-actinin
staining (red). (B) Double immunohistochemistry with Ki-67 and sarcomeric α-actinin
antibodies for the peri-infarct regions and quantitative analysis (n = 7 each; *p < 0.05, **p <
0.01). Arrows indicate Ki-67-positive cardiomyocytes. Bars = 20 μm. (C) Terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay with sarcomeric α-
actinin staining for the peri-infarct regions and quantitative analysis (n = 7 each; *p <
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0.05, **p < 0.01). Bars = 50µm. (D-E) Quantitative reverse transcriptase polymerase chain
reaction analyses with peri-infarct tissues injected with PBS, UC, or EC. EC transplantation
showed highest expression of most angiogenic factors (D) and anti-inflammatory factors (E)
and lowest expression of pro-inflammatory factors (F). Data are presented as fold
differences from the PBS group (n = 5 each; *p < 0.05; **p < 0.01). Other abbreviations as in
Figures 1, 3, and 4.
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Figure 6. Cultured CD31+ Cells Showed Higher Engraftment and Endothelial
Transdifferentiation Capacity in the Ischemic Heart
(A-B) Histological analyses of engrafted cells in the heart sections 4 weeks after EC or UC
(1,1∼-dioctadecyl-3,3,3∼,3∼-tetramethylindocarbocyanine perchlorate [Dil]-labeled, red
fluorescence) injection. (A) EC had higher retention compared with UC. n = 5 each. *p <
0.05. (B) Confocal microscopic examination demonstrated that injected UC-CD31+ cells
(upper panel) or EC-CD31+ cells (lower panel) were colocalized with ILB4 (white arrows)
using 3-dimensional z-stacked orthogonal and mul-tipanel images. Arrows indicate
colocalized cells and arrowheads, engrafted cells in the perivascular areas. Quantifications
of Dil and ILB4-double positive cells are shown on the right. n = 5 each. *p < 0.05. (C-D)
Flow cytometry analyses of digested cardiac tissues at 4 weeks. (C) Higher engraftment of
EC compared with UC occurred, n = 5 each. *p < 0.05. (D) Quantification of Dil and ILB4
double-positive cells showing a higher rate of endothelial transdifferentiation in EC
compared with UC-injected hearts. n = 5 each. *p < 0.05. P1 gating represents ILB4+
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fraction and P2 gating double-positive population for Dil and ILB4. DAPI = 4∼,6-
diamidino-2-phenylindole. Other abbreviations as in Figures 1 and 5.
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Figure 7. Engraftment and Endothelial Transdifferentiation Capacity at 1 Year in the Ischemic
Heart
(A) Cardiac tissues were harvested at 1 year after injection with Dil-labeled EC. Confocal
microscopic examination showed perivascular localization of injected EC as well as
colocalized Dil-labeled EC (red) with ILB4-stained endothelial cells (green) in vessels in z-
stacked orthogonal and multipanel images. Blue, DAPI. (B) Flow cytometry analysis
showing presence of Dil-labeled EC in hearts at 1 year after EC injection (n = 5 each). Heart
tissues were harvested at 1 year and digested with an enzyme cocktail. (C) Flow cytometry
analysis demonstrating Dil and ILB4 double-positive cells showing endothelial
transdifferentiation of injected Dil-labeled EC. P1 gating represents the ILB4+ fraction and
P2 gating represents the cell population double positive for both Dil and ILB4. Other
abbreviations as in Figures 1, 5, and 6.
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Central Illustration. Enhanced therapeutic effects of BM-derived CD31+ cells for cardiac and
vascular repair
The bone marrow-derived CD31+ cells cultured in endothelial cell medium (EC-CD31+
cells) showed higher adhesion and angiogenic activities and low inflammatory properties in
vitro compared with uncultured or other cultured CD31+ cells. When implanted into mouse
myocardial infarction (MI) or hindlimb ischemia (HLI) models, EC-CD31+ cells improved
cardiac function and repaired limb ischemia to a greater extent than uncultured CD31+ cells.
Mechanistically, injected EC-CD31+ cells induced higher retention, neovascularization,
cardiac protection, and cardiomyocyte proliferation, and lower inflammatory reactions.
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